At Miami Cancer Institute, every lung cancer patient receives molecular analysis to better understand the cancer subtype and help identify the best treatment plan using immunotherapy and other advanced therapies. We believe this is a critical step, as every lung cancer case is different, and modern treatment methods depend on careful and accurate analysis.
Miami Cancer Institute can provide access to clinical trials not widely available elsewhere. Clinical trials find new ways to treat and diagnose cancer and are ongoing. If an appropriate trial is available, we will talk to you about the benefits and risks.
At Miami Cancer Institute, we understand that the true definition of compassionate care is that nothing is more important than the patient sitting in front of you. We are ready to care for you.
Argenis Herrera, M.D., is a board-certified thoracic surgeon at Miami Cancer Institute, part of Baptist Health.
Dr. Herrera specializes in general and oncologic thoracic surgery with an emphasis on minimally invasive procedures, including robotic, laparoscopic, thoracoscopic and endoscopic surgery. Dr. Herrera has a special interest in benign and malignant esophageal diseases of the lung and esophagus.
He strives to provide patients with the most advanced technology and knowledge possible to treat their health issues while spending time listening to their concerns, fears and questions with compassion. As a trusted advocate, he helps patients make the best treatment decisions possible for their unique circumstances.
A passionate soccer fan. Dr. Herrera also enjoys baseball, basketball and football. He also likes spending time with family, walking and riding his bike by the beach, traveling to other countries to explore their culture and listening to music of many different genre — from salsa to rock.
As Florida's only member of the Memorial Sloan Kettering (MSK) Cancer Alliance, Miami Cancer Institute is part of a deep and functional collaboration that affords patients access to innovative treatments right here at home and ensures that the standards of care developed by our multidisciplinary disease management team match those at MSK.